RESUMO
The magnitude of the topic of melanocytic nevi (MN) is directly related to its relevance in everyday clinical work. The different MN have different prognostic significance in regard to comorbidity and possible risk of transformation. In addition to the criteria of the ABCDE rule, relevant criteria in the assessment of an MN are the time of occurrence, the growth tendency, the distribution and the comparison with other MN of the respective individual. The present CME article provides an overview of the knowledge that has been gained with regard to the development and genetic background of MN and any risk of degeneration that may exist. In addition, certain clinical and/or dermatoscopic features may provide the clinician with a decision-making aid in the management of different MNs.
Assuntos
Melanoma , Nevo Pigmentado , Neoplasias Cutâneas , Humanos , Nevo Pigmentado/diagnóstico , Prognóstico , Neoplasias Cutâneas/diagnósticoRESUMO
Basal cell carcinoma (BCC) is the most common malignant tumor in light-skinned people and amounts to about 75 % of all cases of skin cancer. Increasing incidence rates have been reported for decades all over the world. The main risk factors include UV radiation, male sex, light skin type, advanced age, long-term immunosuppression, a positive individual or family history, and certain genodermatoses. BCC metastasizes only rarely, and its mortality is low, but it is associated with significant morbidity. Genetic mutations especially in the hedgehog pathway play an important role in BCC pathogenesis. Non-invasive procedures such as optical coherence tomography or confocal laser scan microscopy are increasingly utilized for diagnostics in addition to visual inspection and dermatoscopy, but only in exceptional cases can histological confirmation of the diagnosis be dispensed with. Various clinical and histological subtypes have been defined. Differentiating between BCC with high and low risk of recurrence has a significant influence on the choice of treatment. Most BCC can be treated effectively and safely with standard surgery, or in selected cases with topical treatment. Locally advanced and metastasized BCC must be treated with radiation or systemic therapy. Radiation is also an option for older patients with contraindications for surgery. The hedgehog inhibitors vismodegib and sonidegib are currently approved for systemic therapy of BCC in Europe. Approval for the PD1 inhibitor cemiplimab as second-line therapy is expected in the near future.
Assuntos
Antineoplásicos , Carcinoma Basocelular , Neoplasias Cutâneas , Anilidas/uso terapêutico , Antineoplásicos/uso terapêutico , Carcinoma Basocelular/tratamento farmacológico , Carcinoma Basocelular/terapia , Proteínas Hedgehog , Humanos , Masculino , Recidiva Local de Neoplasia , Neoplasias Cutâneas/tratamento farmacológico , Neoplasias Cutâneas/terapiaRESUMO
This is a case series of 8 patients with palmoplantar pustulosis. These patients were treated with the phosphodiesterase4 inhibitor apremilast at our psoriasis outpatient clinic at the dermatological department of the University Hospital Innsbruck and we compared and documented the clinical response using an Investigator's Global Assessment (IGA) score over several months. This disease is characterized by its strong negative impact on the quality of life in affected patients, and by its resistance to therapy and its high relapse rate. Therapy options are relatively rare or off label. Apremilast is a safe and effective therapeutic approach in palmoplantar pustulosis.
Assuntos
Exantema , Psoríase , Humanos , Psoríase/diagnóstico , Psoríase/tratamento farmacológico , Qualidade de Vida , Talidomida/efeitos adversos , Talidomida/análogos & derivadosAssuntos
Albuminas/uso terapêutico , Antineoplásicos/uso terapêutico , Braquiterapia , Neoplasias de Cabeça e Pescoço/tratamento farmacológico , Hemangiossarcoma/tratamento farmacológico , Paclitaxel/uso terapêutico , Neoplasias Cutâneas/tratamento farmacológico , Idoso , Terapia Combinada , Neoplasias Faciais/tratamento farmacológico , Neoplasias Faciais/radioterapia , Feminino , Neoplasias de Cabeça e Pescoço/radioterapia , Hemangiossarcoma/radioterapia , Humanos , Neoplasias Pulmonares/secundário , Recidiva Local de Neoplasia , Indução de Remissão , Couro Cabeludo , Neoplasias Cutâneas/radioterapiaRESUMO
In this case report, we describe a patient with an inoperable mucosal melanoma of the sinonasal cavity who achieved an ongoing complete response to combined immunotherapy with ipilimumab and nivolumab after initial pseudoprogression. Despite massive enlargement of the tumor 9 weeks after treatment initiation, we decided to continue with checkpoint inhibitor immunotherapy because of lacking potent therapeutic alternatives and the possibility of pseudoprogression. In the computed tomography scan 3 months later, the tumor was no longer detectable. To date, the patient is still in remission. However, she developed severe immune-related thrombocytopenia and neutropenia that are rarely encountered with checkpoint inhibitor immunotherapy. Thrombocytopenia did not respond to corticosteroids, but rapidly improved after the administration of single-dose intravenous immunoglobulin. This exceptional case highlights the effectiveness of combined immunotherapy with ipilimumab and nivolumab in mucosal melanoma, the phenomenon of pseudoprogression, as well as the rare event of immune-related hematological side effects.